Your session is about to expire
← Back to Search
CPB Management & Anticoagulation for Obese Patients
Study Summary
This trial will help determine if using lean body mass to determine pump flow rate and/or heparin dosage is safe and effective for obese patients undergoing CPB.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2008 Phase 4 trial • 541 Patients • NCT00277394Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My BMI is 30 or higher.I will be using desmopressin around the time of my surgery.My BMI is 30 or higher.I am scheduled for heart surgery.I am scheduled for a heart bypass surgery without using a heart-lung machine.I am scheduled for a procedure that involves cooling my body and stopping my blood circulation.My liver tests (AST or ALT) are not more than 2 times the normal limit.I have a known inherited bleeding disorder.I have a major narrowing (50% or more) in my carotid artery.I refuse to receive blood transfusions.I have a known deficiency in protein C, S, antithrombin, or have homozygous factor V Leiden.I have an infection in the heart's inner lining.I have had two or more heart surgeries.I need emergency heart surgery within 24 hours due to acute symptoms.My surgery will use my own blood to prime the heart-lung machine.I was given a blood thinner injection less than 24 hours before surgery.I am not pregnant, breastfeeding, planning to become pregnant, or failing to use birth control.I have taken clopidogrel, ticagrelor, or prasugrel recently before surgery.I am 18 years old or older.I had a major heart attack within the last week.My blood clotting time is longer due to my medication.I have kidney failure or am on dialysis.I have a blood clot condition that is not a heart attack.I am resistant to Heparin.I am scheduled for heart surgery.I am 18 years old or older.I am scheduled for heart surgery.I have a history of stroke or blood clots, including in my legs or lungs.I was given a specific heart medication within 24 hours before surgery.My BMI is 30 or higher.
- Group 1: Control group
- Group 2: Intervention group A
- Group 3: Intervention group B
- Group 4: Intervention group C
- Approved for 20 Other Conditions - This treatment demonstrated efficacy for 20 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What additional investigations have been conducted on the use of Heparin?
"To date, 36 clinical trials have been launched to investigate the efficacy of Heparin. 12 of these studies are currently in their final phase and 367 sites across the world are conducting research on this medication, with a concentration around Sherbrooke, Quebec."
Is enrollment for this experiment currently available?
"Indeed, current data from clinicaltrials.gov confirms that this research project is presently enrolling participants. The trial was first posted on August 21st 2015 and updated most recently on August 18th 2022. A total of 410 individuals need to be enrolled at one medical centre."
What ailments is Heparin regularly employed to combat?
"Heparin is often utilized to treat medical equipment, but also has a range of therapeutic applications including treating sprains, atrial fibrillation, and unstable angina pectoris."
Is this an innovative research endeavor?
"Heparin has been studied since 2006, with the first trial conducted by Ash Access Technology. After 415 participants completed Phase 1 of this research, it received its drug approval and currently 36 trials are in progress across 197 cities and 21 countries."
What is the total number of participants currently being recruited for this trial?
"Affirmative. Clinicaltrials.gov data shows that the trial posted on August 21st 2015 is currently attempting to recruit 410 participants from 1 site."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger